MGeneRx is an Artificial Intelligence platform developed by rare disease experts, physicians and engineers that can instantly identify a child’s risk for congenital birth defects using biometric recognition
MGeneRX is an Artificial Intelligence platform developed by rare disease experts, physicians and engineers that can instantly identify a child’s risk for congenital birth defects using biometric recognition
With over 8,000 identified genetic disorders, current common newborn DNA tests only detect approximately 20 of them. We are working to address this, by providing cost effective screening for pediatric patients
Working to reduce parent’s stress and anxiety, we offer instant results, enabling the identification of the presence of a genetic condition and early referral to specialized care. With these capabilities, we help medical professionals to reduce high clinical costs whilst opening opportunities for outreach to rural areas and communities who struggle to find access to genetisist’s who specialize is these disorders
The product has been used and tested on thousands of children from 28 different countries. This has extended our capabilities to spot conditions in a global population.
Our AI Platform currently has close to 90% accuracy in detecting 128 syndromes, including
Using machine learning, we have also discovered new facial landmarks for syndromes previously unknown – continuing our output of expanding clinical knowledge
With over 7,000 identified genetic disorders, current common newborn DNA tests only detect approximately 20 of them. We are working to address this, by providing cost effective screening for pediatric patients
Working to reduce parent’s stress and anxiety, we offer instant results, enabling the identification of the presence of a genetic condition and early referral to specialized care. With these capabilities, we help medical professionals to reduce high clinical costs whilst opening opportunities for outreach to rural areas and communities who struggle to find access to genetisist’s who specialize is these disorders
The product has been used and tested on thousands of children from 28 different countries. This has extended our capabilities to spot conditions in a global population.
Our AI Platform currently has close to 90% accuracy in detecting 128 syndromes, including